Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR).
HIF
glutathione
kidney cancer
nutrition
retinoids
Journal
Molecular carcinogenesis
ISSN: 1098-2744
Titre abrégé: Mol Carcinog
Pays: United States
ID NLM: 8811105
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
14
03
2022
received:
15
10
2021
accepted:
14
04
2022
pubmed:
22
6
2022
medline:
12
8
2022
entrez:
21
6
2022
Statut:
ppublish
Résumé
Research has shown extensive metabolic remodeling in clear cell renal cell carcinoma (ccRCC), with increased glutathione (GSH) levels. We hypothesized that activating transcription factor-4 (ATF4) and the integrated stress response (ISR) induce a metabolic shift, including increased GSH accumulation, and that Vitamin A deficiency (VAD), found in ccRCCs, can also activate ATF4 signaling in the kidney. To determine the role of ATF4, we used publicly available RNA sequencing (RNA-seq) data sets from The Cancer Genomics Atlas. Subsequently, we performed RNA-seq and liquid chromatography-mass spectrometry-based metabolomics analysis of the murine TRAnsgenic Cancer of the Kidney (TRACK) model for early-stage ccRCC. To validate our findings, we generated RCC4 cell lines with ATF4 gene edits (ATF4-knockout [KO]) and subjected these cells to metabolic isotope tracing. Analysis of variance, the two-sided Student's t test, and gene set enrichment analysis were used (p < 0.05) to determine statistical significance. Here we show that most human ccRCC tumors exhibit activation of the transcription factor ATF4. Activation of ATF4 is concomitant with enrichment of the ATF4 gene set and elevated expression of ATF4 target genes ASNS, ALDH1L2, MTHFD2, DDIT3 (CHOP), DDIT4, TRIB3, EIF4EBP1, SLC7A11, and PPP1R15A (GADD34). Transcript profiling and metabolomics analyses show that activated hypoxia-inducible factor-1α (HIF1α) signaling in our TRACK ccRCC murine model also induces an ATF4-mediated ISR. Notably, both normoxic HIF1α signaling in TRACK kidneys and VAD in wild-type kidneys diminish amino acid levels, increase ASNS, TRIB3, and MTHFD2 messenger RNA levels, and increase levels of lipids and GSH. By metabolic isotope tracing in human RCC4 kidney cancer parental and ATF4 gene-edited (ATF4-KO) cell lines, we show that ATF4 increases GSH accumulation in part via activation of the mitochondrial one-carbon metabolism pathway. Our results demonstrate for the first time that activation of ATF4 enhances GSH accumulation, increases purine and pyrimidine biosynthesis, and contributes to transcriptional and metabolic remodeling in ccRCC. Moreover, constitutive HIF1α expressed only in murine kidney proximal tubules activates ATF4, leading to the metabolic changes associated with the ISR. Our data indicate that HIF1α can promote ccRCC via ATF4 activation. Moreover, lack of Vitamin A in the kidney recapitulates aspects of the ISR.
Identifiants
pubmed: 35726553
doi: 10.1002/mc.23437
pmc: PMC9378514
mid: NIHMS1815372
doi:
Substances chimiques
ATF4 protein, human
0
Activating Transcription Factor 4
145891-90-3
Glutathione
GAN16C9B8O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
851-864Subventions
Organisme : NICHD NIH HHS
ID : P01 HD067244
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR076029
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK113088
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA062948
Pays : United States
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
EMBO J. 2010 Jun 16;29(12):2082-96
pubmed: 20473272
Clin Cancer Res. 2007 Dec 15;13(24):7388-93
pubmed: 18094421
Cancer Cell. 2002 Jun;1(5):459-68
pubmed: 12124175
Science. 2020 Apr 24;368(6489):
pubmed: 32327570
Cell Rep. 2018 Aug 7;24(6):1407-1414
pubmed: 30089252
Am J Physiol Endocrinol Metab. 2013 Apr 15;304(8):E789-99
pubmed: 23403946
Cell Metab. 2018 May 01;27(5):1007-1025.e5
pubmed: 29657030
Annu Rev Pathol. 2011;6:345-64
pubmed: 21073338
Cancer Discov. 2011 Aug;1(3):222-35
pubmed: 22037472
Cell Rep. 2018 Oct 30;25(5):1109-1117.e5
pubmed: 30380403
Oncogene. 2015 May 14;34(20):2631-9
pubmed: 25023703
Elife. 2017 Nov 14;6:
pubmed: 29132502
PLoS Comput Biol. 2019 Mar 5;15(3):e1006701
pubmed: 30835723
Cancer Cell. 2016 Jan 11;29(1):104-116
pubmed: 26766592
Mol Cell Biol. 2004 Sep;24(17):7469-82
pubmed: 15314157
Nat Rev Nephrol. 2017 Jul;13(7):410-419
pubmed: 28480903
Am J Surg Pathol. 2011 Oct;35(10):1549-56
pubmed: 21881486
Nat Cell Biol. 2019 Jul;21(7):889-899
pubmed: 31263264
Clin Cancer Res. 2016 Jun 1;22(11):2791-801
pubmed: 26783287
Nat Rev Mol Cell Biol. 2012 Jan 18;13(2):89-102
pubmed: 22251901
Nat Cell Biol. 2013 May;15(5):481-90
pubmed: 23624402
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
Arch Physiol Biochem. 2018 May;124(2):131-138
pubmed: 28857622
Cell Rep. 2018 Sep 4;24(10):2596-2605.e5
pubmed: 30184495
Cell Metab. 2016 Oct 11;24(4):640-641
pubmed: 27732838
Blood Cancer Discov. 2022 Jan;3(1):50-65
pubmed: 35019856
EMBO Rep. 2016 Oct;17(10):1374-1395
pubmed: 27629041
Oncogene. 2007 Jul 19;26(33):4749-60
pubmed: 17297441
Mol Cancer Res. 2015 May;13(5):870-8
pubmed: 25715653
Arch Pathol Lab Med. 2017 Dec;141(12):1615-1632
pubmed: 28767283
Nat Commun. 2020 Aug 17;11(1):4111
pubmed: 32807776
Cell Rep. 2017 May 9;19(6):1083-1090
pubmed: 28494858
Genome Res. 2014 May;24(5):869-84
pubmed: 24515121
Cell Rep. 2018 Apr 3;23(1):313-326.e5
pubmed: 29617669
Oncogene. 2018 Oct;37(40):5435-5450
pubmed: 29872221
Nat Genet. 2013 Aug;45(8):860-7
pubmed: 23797736
Mol Biol Cell. 2013 Aug;24(15):2477-90
pubmed: 23761072
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1027-1032
pubmed: 28082722
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Invest New Drugs. 2020 Oct;38(5):1383-1389
pubmed: 31898184
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
Cancer Res. 2013 May 1;73(9):2916-25
pubmed: 23447580
Cell Rep. 2017 Mar 21;18(12):2893-2906
pubmed: 28329682
Cancer Res. 2015 Jun 15;75(12):2541-52
pubmed: 25952651
Cancer Res. 2021 Aug 1;81(15):4066-4078
pubmed: 34183356
Mol Biol Cell. 2016 May 1;27(9):1536-51
pubmed: 26960794
Cancer Res. 2001 Mar 15;61(6):2774-81
pubmed: 11289161
Elife. 2021 Mar 01;10:
pubmed: 33646118
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Cell. 2018 Apr 19;173(3):611-623.e17
pubmed: 29656891
Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:379-403
pubmed: 30625281
Cancer Discov. 2014 Dec;4(12):1406-17
pubmed: 25186948
Cell Metab. 2016 Jun 14;23(6):1140-1153
pubmed: 27211901
Cancer Res. 2011 Nov 1;71(21):6848-56
pubmed: 21908555
EMBO J. 2005 Oct 5;24(19):3470-81
pubmed: 16148948
Science. 2016 Feb 12;351(6274):728-733
pubmed: 26912861
J Cell Biol. 2017 Jul 3;216(7):2027-2045
pubmed: 28566324
Trends Endocrinol Metab. 2017 Nov;28(11):794-806
pubmed: 28797581
Cell Metab. 2011 Dec 7;14(6):768-79
pubmed: 22100406
Oncogene. 2017 Oct 5;36(40):5593-5608
pubmed: 28553953